RxDoctor Payments Data

Syed Mobin, MD

Pulmonary Disease · Orlando, FLNPI 1689653479

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 35.6% of the total. Reporting peaked in 2023 at $5,708 and has fallen 80.4% since, to $1,119 in 2025.

$19,570in general payments, 2019–2025

Across 382 payments — averaging $51.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$7K
  • Bayer$5K
  • GSK$1K
  • AstraZeneca$1K
  • Medical Device Business Services, Inc.$851
  • Boehringer Ingelheim$622
  • plus $4K from 36 others
$468,665in research payments, 2019–2025

Across 134 payments — averaging $3497.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$323K
  • Amgen$92K
  • Kadmon Corporation LLC$33K
  • Genentech, Inc.$21K
  • Novartis$280

What the payments were for

  • Consulting fees$4,83025%
  • Speaking & faculty fees$4,70924%
  • Travel & lodging$1,8559%
  • Food & beverage$7,36338%
  • Education$7844%
  • Gifts$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,570 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$384,549
Medicare patients
1,415
Services billed
3,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat47$658,545
OpsumitMacitentan33$429,550
OfevNintedanib Esylate33$426,506
Tyvaso DpiTreprostinil15$351,621
UptraviSelexipag13$287,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter313$264,646
Ambrisentan88$204,897
Orenitram ErTreprostinil Diolamine12$179,043
TezspireTezepelumab-Ekko16$66,127
Tadalafil38$50,545
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$48,664
Breo ElliptaFluticasone/Vilanterol80$45,210
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$27,381
Spiriva RespimatTiotropium Bromide15$14,261
SymbicortBudesonide/Formoterol Fumarate31$9,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$6,968$717,43846 claims
BayerAdempas$5,104$658,54547 claims
Boehringer IngelheimOfev, Spiriva Respimat$622$440,76848 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,207$337,237431 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$1,138$129,359117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →